Legacy Wealth Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$575K Buy
5,210
+1,447
+38% +$140K 0.13% 239
2026
Q2
$295K Sell
3,763
-64
-2% -$4.36K 0.06% 322
2026
Q1
$247K Buy
3,827
+138
+4% +$9.73K 0.06% 334
2025
Q4
$248K Buy
3,689
+59
+2% +$3.97K 0.06% 336
2025
Q3
$266K Sell
3,630
-1,325
-27% -$88K 0.06% 327
2025
Q2
$258K Buy
4,955
+1,010
+26% +$57.5K 0.07% 328
2025
Q1
$252K Buy
+3,945
New +$229K 0.07% 318
2024
Q4
– Sell
-3,858
Closed -$221K – 354
2024
Q3
$221K Buy
+3,858
New +$221K 0.06% 332

Other funds holding HALO

Legacy Wealth Asset Management's HALO Position: Q3 2026 in Review

Legacy Wealth Asset Management increased its Halozyme (HALO) stake by 38% in Q3 2026, buying an estimated $140K and bringing the position to 5,210 shares worth $575K. The position accounts for 0.13% of the portfolio, ranked #239.

Legacy Wealth Asset Management first reported a position in HALO in Q3 2024 and has held it in 8 quarters since. 31 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Legacy Wealth Asset Management held 5,210 shares of Halozyme worth $575K as of Q3 2026.
  • Legacy Wealth Asset Management bought 1,447 Halozyme shares in Q3 2026, an estimated $140K.
  • Halozyme made up 0.13% of Legacy Wealth Asset Management's portfolio in Q3 2026, its #239 holding.
  • Legacy Wealth Asset Management first reported a position in Halozyme in Q3 2024 and has held it in 8 quarters since.
  • 31 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Legacy Wealth Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.